EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Sacubitril/Valsartan for the Treatment of Non-Obstructive Hypertrophic Cardiomyopathy: An Open Label Randomized Controlled Trial (SILICOFCM)

Lazar Velicki, Dejana Popovic, Nduka C Okwose iD, Andrej Preveden, Milorad Tesic, Maria Tafelmeier, Sarah J Charman, Fausto Barlocco, Guy A MacGowan, Petar M Seferovic, Nenad Filipovic, Arsen Ristic und 4 weitere

European Journal of Heart Failure · 2024

DOI: 10.1002/ejhf.3291 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Lazar Velicki und 15 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia. Hauptthemen laut MEDLINE: Valsartan, Biphenyl Compounds, Aminobutyrates, Drug Combinations. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Sacubitril/valsartan treatment reduces mortality and hospitalizations in heart failure with reduced ejection fraction but has limited application in hypertrophic cardiomyopathy (HCM). The aim of this study was to evaluate the effect of sacubitril/valsartan on peak oxygen consumption (VO2) in patients with non-obstructive HCM. Methods and results This is a phase II, randomized, open-label multicentre study that enrolled adult patients with symptomatic non-obstructive HCM (New York Heart Association class I–III) who were randomly assigned (2:1) to receive sacubitril/valsartan (target dose 97/103 mg) or control for 16 weeks. The primary endpoint was a change in peak VO2. Secondary endpoints included echocardiographic measures of cardiac structure and function, natriuretic peptides and other cardiac biomarkers, and Minnesota Living with Heart Failure quality of life. Between May 2018 and October 2021, 354 patients were screened for eligibility, 115 patients (mean age 58 years, 37% female) met the study inclusion criteria and were randomly assigned to sacubitril/valsartan (n = 79) or control (n = 36). At 16 weeks, there was no significant change in peak VO2 from baseline in the sacubitril/valsartan (15.3 [4.3] vs. 15.9 [4.3] ml/kg/min, p = 0.13) or control group (p = 0.47). No clinically significant changes were found in blood pressure, cardiac structure and function, plasma biomarkers, or quality of life.

Conclusion

In patients with HCM, a 16-week treatment with sacubitril/valsartan was well tolerated but had no effect on exercise capacity, cardiac structure, or function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValsartanBiphenyl CompoundsAminobutyratesDrug CombinationsCardiomyopathy, HypertrophicAngiotensin Receptor AntagonistsHumansMaleFemaleMiddle AgedStroke VolumeOxygen ConsumptionAgedTetrazolesEchocardiographyTreatment OutcomeQuality of LifeHeart Failure

Stichwörter der Autor:innen

Exercise capacityHypertrophic cardiomyopathySacubitril/valsartan

Substanzen

ValsartanBiphenyl CompoundsAminobutyratessacubitril and valsartan sodium hydrate drug combinationDrug CombinationsAngiotensin Receptor AntagonistsTetrazoles

Autor:innen und Institutionen

  • Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
  • Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia.
  • Cardiology Department, Faculties of Medicine and Pharmacy, University of Belgrade, Serbia.
  • Cardiovascular Research, Translational and Clinical Research and Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Research Centre for Health and Life Sciences, Institute of Health and Wellbeing, Faculty of Health and Life Science, Coventry University, Coventry, UK.
  • Department of Internal Medicine II, University Medical Centre Regensburg, Regensburg, Germany.

ORCID-Profile: Nduka C Okwose, Djordje G Jakovljevic

Förderung

  • Horizon 2020 Framework Programme

Zitieren

APA

Velicki, L., Popovic, D., Okwose, N. C., Preveden, A., Tesic, M., Tafelmeier, M., Charman, S. J., Barlocco, F., MacGowan, G. A., Seferovic, P. M., Filipovic, N., Ristic, A., Olivotto, I., Maier, L. S., Jakovljevic, D. G., & SILICOFCM Investigators (2024). Sacubitril/Valsartan for the Treatment of Non-Obstructive Hypertrophic Cardiomyopathy: An Open Label Randomized Controlled Trial (SILICOFCM). European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3291

Vancouver

Velicki L, Popovic D, Okwose NC, Preveden A, Tesic M, Tafelmeier M, et al. Sacubitril/Valsartan for the Treatment of Non-Obstructive Hypertrophic Cardiomyopathy: An Open Label Randomized Controlled Trial (SILICOFCM). European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3291

BibTeX
@article{Velicki2024,
  author = {Velicki, Lazar and Popovic, Dejana and Okwose, Nduka C and Preveden, Andrej and Tesic, Milorad and Tafelmeier, Maria and Charman, Sarah J and Barlocco, Fausto and MacGowan, Guy A and Seferovic, Petar M and Filipovic, Nenad and Ristic, Arsen and Olivotto, Iacopo and Maier, Lars S and Jakovljevic, Djordje G and SILICOFCM Investigators, SILICOFCM Investigators},
  title = {Sacubitril/Valsartan for the Treatment of Non-Obstructive Hypertrophic Cardiomyopathy: An Open Label Randomized Controlled Trial (SILICOFCM)},
  journal = {European Journal of Heart Failure},
  year = {2024},
  doi = {10.1002/ejhf.3291}
}
Kostenlos starten →